Insulet Gestione

Gestione criteri di controllo 3/4

Insulet Il CEO è Jim Hollingshead, nominato in Jun2022, e ha un mandato di 2.42 anni. la retribuzione annua totale è $ 12.38M, composta da 6.8% di stipendio e 93.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.025% delle azioni della società, per un valore di € 4.32M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 4 anni.

Informazioni chiave

Jim Hollingshead

Amministratore delegato

US$12.4m

Compenso totale

Percentuale dello stipendio del CEO	6.8%
Mandato del CEO	2.4yrs
Proprietà del CEO	0.02%
Durata media del management	2.4yrs
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jim Hollingshead rispetto agli utili di Insulet?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$421m
Jun 30 2024	n/a	n/a	US$395m
Mar 31 2024	n/a	n/a	US$234m
Dec 31 2023	US$12m	US$842k	US$206m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$63m
Mar 31 2023	n/a	n/a	US$600k
Dec 31 2022	US$11m	US$440k	US$5m
Sep 30 2022	n/a	n/a	US$17m
Jun 30 2022	n/a	n/a	US$35m
Mar 31 2022	n/a	n/a	US$45m
Dec 31 2021	US$290k	n/a	US$17m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	US$9m
Dec 31 2020	US$259k	n/a	US$7m
Sep 30 2020	n/a	n/a	US$29m
Jun 30 2020	n/a	n/a	US$18m
Mar 31 2020	n/a	n/a	US$5m
Dec 31 2019	US$261k	n/a	US$12m

Compensazione vs Mercato: La retribuzione totale di Jim ($USD 12.38M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 4.90M ).

Compensazione vs guadagni: La retribuzione di Jim è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jim Hollingshead (61 yo)

2.4yrs

Mandato

US$12,379,765

Compensazione

Dr. James R. Hollingshead, also known as Jim, Ph.D. had been President of Sleep & Respiratory Care Business at ResMed Inc. since July 2020 until May 05, 2022 and served as its President of Sleep Business s...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
James Hollingshead	President	2.4yrs	US$12.38m	0.025% € 4.3m
Lauren Budden	Group VP	5.6yrs	US$1.44m	0.0061% € 1.1m
Mark Field	Senior VP & CTO	1.3yrs	US$2.37m	0.014% € 2.4m
John Kapples	Senior VP & General Counsel	5.7yrs	US$2.47m	0.021% € 3.7m
Eric Benjamin	Executive VP	6.8yrs	US$3.14m	0.024% € 4.2m
Ana Chadwick	Executive VP	less than a year	Nessun dato	0.00014% € 24.3k
Prem Singh	Senior Vice President of Global Operations	1.8yrs	Nessun dato	0.0052% € 903.0k
Deborah Gordon	Vice President of Investor Relations	9.8yrs	Nessun dato	Nessun dato
Laetitia Cousin	Senior VP of Regulatory Affairs	1.9yrs	Nessun dato	0.0044% € 767.8k
Angela Wiczek	Senior Director of Corporate Communications	no data	Nessun dato	Nessun dato
Philip Hildale	Senior Vice President of Sales & Customer Care	9.8yrs	Nessun dato	Nessun dato
Andrew Isaacson	Senior VP of Strategy & Corporate Development	less than a year	Nessun dato	Nessun dato

2.4yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di GOV è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
James Hollingshead	President	5.3yrs	US$12.38m	0.025% € 4.3m
Elizabeth Weatherman	Independent Director	2.8yrs	US$322.50k	0.0040% € 686.3k
Timothy Scannell	Independent Chairman	10.3yrs	US$387.10k	0.042% € 7.2m
Robert Sherwin	Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Howard Wolpert	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Margaret Lawlor	Member of Educator Advisory Board	no data	Nessun dato	Nessun dato
Camille Izlar	Member of Educator Advisory Board	no data	Nessun dato	Nessun dato
Mary Halvorson	Member of Educator Advisory Board	no data	Nessun dato	Nessun dato
Steven Edelman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Anne Daly	Member of Educator Advisory Board	no data	Nessun dato	Nessun dato
John Buse	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Timothy Stonesifer	Independent Director	less than a year	Nessun dato	Nessun dato

4.0yrs

Durata media

61yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GOV sono considerati esperti (durata media dell'incarico 4 anni).

Insulet Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Chairman recently sold €1.0m worth of stock

Independent Chairman recently sold €1.2m worth of stock

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Announces Board Changes

Director & Advisor recently sold €2.3m worth of stock

Recent updates

Now 25% overvalued after recent price rise

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Omnipod 5 App for Iphone Now Fully Available in the United States

Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024

Independent Chairman recently sold €1.0m worth of stock

Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Second quarter 2024 earnings released: EPS: US$2.69 (vs US$0.39 in 2Q 2023)

Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024

Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Independent Chairman recently sold €1.2m worth of stock

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.74 (vs US$0.34 in 1Q 2023)

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes

Investor sentiment deteriorates as stock falls 17%

Full year 2023 earnings released: EPS: US$2.96 (vs US$0.066 in FY 2022)

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Now 20% undervalued

Insulet Corporation Announces Board Changes

Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024

Director & Advisor recently sold €2.3m worth of stock

Now 21% undervalued after recent price drop

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Third quarter 2023 earnings released: EPS: US$0.74 (vs US$0.075 loss in 3Q 2022)

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

New minor risk - Share price stability

Insulet Corporation Announces CFO Transition

Insulet Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany

Second quarter 2023 earnings released: EPS: US$0.39 (vs US$0.51 loss in 2Q 2022)

Insulet Corporation to Report Q2, 2023 Results on Aug 08, 2023

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery System Is Now Available in the United Kingdom

Insider recently bought €933k worth of stock

Bret Christensen, Executive Vice President, Chief Commercial Officer Will Be Leaving Insulet Corporation

First quarter 2023 earnings released: EPS: US$0.34 (vs US$0.40 in 1Q 2022)

Executive VP recently sold €367k worth of stock

Full year 2022 earnings released: EPS: US$0.066 (vs US$0.25 in FY 2021)

Insulet Corporation (NasdaqGS:PODD) acquired Assets of Automated Glucose Control LLC for $25 million.

Insulet Corporation to Report Q4, 2022 Results on Feb 23, 2023

Insulet Corporation Announces Executive Changes

Executive VP & Chief Commercial Officer recently sold €854k worth of stock

Insulet Corporation Announces Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System

Third quarter 2022 earnings released: US$0.075 loss per share (vs US$0.18 profit in 3Q 2021)

Insulet Corporation Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022

Insulet Corporation Provides Revenue Guidance for the Quarter Ending December 31, 2022

Insulet Corporation to Report Q3, 2022 Results on Nov 03, 2022

Executive VP & Chief Commercial Officer recently sold €768k worth of stock

Insulet Corporation Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Second quarter 2022 earnings released: US$0.51 loss per share (vs US$0.38 loss in 2Q 2021)

Insulet Corporation Provides Revenue Guidance for the Quarter Ending September 30, 2022 and Year Ending December 31, 2022

Insulet Corporation Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System

Insulet Corporation to Report Q2, 2022 Results on Aug 04, 2022

Executive VP & COO recently sold €1.2m worth of stock

Omnipod(R) 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

First quarter 2022 earnings released

Insulet Corporation Provides Revenue Guidance for the Quarter Ending June 30, 2022 and Full Year Ending December 31, 2022

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

Insulet Corporation, Annual General Meeting, May 24, 2022

Insulet Corporation to Report Q1, 2022 Results on May 05, 2022

Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2022 and Year Ending December 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations